Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company's unique business model centered around royalties and healthcare assets.
康泰菲茨傑開始對Innoviva，Inc. (納斯達克: Innoviva) 進行覆蓋，並稱贊該公司基於專利和醫療保健資產的獨特業務模型。
The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. "We believe their manufacturing complexity provides further protection from potential competitors," Cantor analyst writes.
該公司從葛蘭素史克(AST:GSK)收取哮喘和慢性阻塞性肺病等常見病產品 (包括Relvar / Breo和Anoro) 的版稅，在2023年的銷售額超過20億美元。康泰分析師寫道:“我們認爲，它們的製造複雜性爲潛在競爭對手提供了進一步的保護。”
Cantor projects around $1.1 billion of 5-year projected royalty revenues from GSK and initiates Innoviva with an Overweight rating.
康泰預計從GSK獲得大約11億美元的5年預計版稅收入，並以超配的評級啓動Innoviva。
The analyst says Breo and Anoro have exceeded expectations, even during challenging times such as the COVID-19 pandemic. They are experiencing growth in markets outside the U.S., with primary patents valid until 2025 and secondary patents extending to 2030 and 2033.
分析師表示，Breo和Anoro甚至在COVID-19大流行等困難時期也超出了預期。這些產品在美國以外的市場上正經歷着增長，主要專利有效期至2025年，第二專利延長至2030年和2033年。
The company's critical care and infectious disease platform generated over $70 million in revenues last year and is growing. Cantor adds that given the market dynamics and reimbursement challenges, these products are difficult for companies to sell individually.
該公司的重症護理和傳染病平台去年創造了超過7000萬美元的收入，目前正在增長中。康泰補充說，鑑於市場動態和報銷挑戰，這些產品難以單獨銷售。
The company plans to expand Innoviva Specialty Therapeutics' product portfolio through organic and inorganic growth opportunities.
該公司計劃通過有機和非有機增長機會擴大Innoviva Specialty Therapeutics 的產品組合。
Innoviva's lead pipeline product is zoliflodacin, a potential oral drug for uncomplicated gonorrhea, and the company is on track to submit an FDA marketing application in early 2025.
Innoviva的主導管道產品是zoliflodacin，這是一種治療單純性淋病的口服藥物，該公司計劃在2025年初提交FDA的營銷申請。
Zoliflodacin could achieve over $500 million of annual peak sales in the U.S.
Zoliflodacin在美國的年銷售額可能達到5億美元以上。
Cantor says, "Although INVA has not publicly discussed exactly what it will do with its cash, we would not be surprised if the company considers a roll-up of another underappreciated industry like it did with Innoviva Specialty Therapeutics."
康泰稱：“雖然INVA還沒有公開討論過它將如何處理現金，但如果公司考慮像Innoviva Specialty Therapeutics一樣的另一個被低估行業的一體化，我們不會感到驚訝。”
Price Action: INVA shares are up 1.61% at $16.42 at last check Tuesday.
股價走勢: INVA股份於上週二最後一次交易中上漲了1.61％，報16.42美元。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。